Management of Migraine in Pregnancy

A Comprehensive Evidence-Based Clinical Review

Pain Spa

Introduction

Migraine affects up to 20% of women of reproductive age and is one of the most common neurological conditions encountered during pregnancy. Its management presents a unique clinical challenge: every treatment decision must balance effective maternal symptom control against the imperative to minimise fetal drug exposure. Both undertreated and poorly managed migraine carry consequences, and an individualised, evidence-based approach guided by shared decision-making is essential.

The natural history of migraine in pregnancy is generally favourable. According to the American College of Obstetricians and Gynecologists (ACOG) and the International Headache Society (IHS), up to 80–90% of pregnant patients experience spontaneous reduction or remission of migraine by the second trimester. This improvement is thought to reflect the stabilising effect of sustained high oestrogen levels on trigeminovascular pathways. However, approximately 8% of women experience increased frequency or severity during pregnancy, and migraine can be at its worst in the first trimester before hormonal levels plateau.

A key principle should be made clear from the outset: disabling migraine must not be left untreated in pregnancy. Undertreated migraine can lead to dehydration, poor sleep, stress, analgesic overuse, repeated healthcare contacts, and potentially adverse obstetric outcomes. The goal is therefore not to withhold treatment, but to identify the safest effective treatment for the individual patient at the relevant stage of pregnancy.

Migraine and Pregnancy Outcomes — Understanding the Risks

Migraine in pregnancy is not simply a pain disorder in isolation. Women with migraine, particularly migraine with aura, face an increased risk of several pregnancy-related complications. These associations matter clinically because they support the need both for adequate migraine control and for heightened obstetric awareness throughout pregnancy.

Obstetric and Vascular Risks

This does not mean that most pregnant women with migraine will develop these complications, but it does mean that migraine should not be dismissed as a trivial symptom. In practical terms, women with migraine, especially migraine with aura, merit greater awareness of blood pressure, fetal growth, preeclampsia symptoms, and other vascular risk factors throughout pregnancy.

Preconception Counselling

For women of childbearing age with migraine who are planning a pregnancy, structured preconception counselling is strongly recommended. This creates an opportunity to review current medications, discontinue potentially harmful agents in good time, transition to safer alternatives where necessary, and establish non-pharmacological strategies before pregnancy begins. It also provides an opportunity to explain the likely natural history of migraine during pregnancy and to create a clear plan should attacks persist or worsen.

Medication Review and Transition

All preventive medications should be reviewed carefully before conception. Certain agents carry clear teratogenic risk and should be discontinued well before pregnancy is attempted. Valproate and topiramate are the most important examples. These agents are associated with neural tube defects, orofacial clefts, and adverse neurodevelopmental outcomes, and they should be stopped before conception with transition to safer alternatives.

ACE inhibitors and angiotensin receptor blockers, such as candesartan, are also contraindicated in pregnancy because of fetal renal toxicity and associated complications. They should be discontinued before conception rather than after pregnancy is confirmed.

CGRP-targeted therapies require specific counselling. Monoclonal antibodies such as erenumab, fremanezumab, galcanezumab, and eptinezumab are not recommended during pregnancy because safety data remains insufficient and IgG antibodies cross the placenta. Since these drugs have long half-lives, discontinuation is advised at least six months before conception to allow adequate clearance. Oral gepants are also not recommended in pregnancy, but because they have much shorter half-lives, they clear within days of discontinuation. That shorter clearance window may be relevant when counselling women in the periconception period, even though they should still be stopped before conception.

Where preventive treatment is still needed, transition to pregnancy-compatible options should be considered. Propranolol, often preferred by the American Headache Society, and verapamil, which ACOG considers a first-line option, are the most established choices in this setting. The decision to use either should still be individualised according to maternal comorbidity, cardiovascular profile, and previous treatment response.

Non-Pharmacological Optimisation Before Pregnancy

Preconception is also the ideal time to establish non-pharmacological measures that will continue to be important throughout pregnancy. Trigger identification through a headache diary, regular sleep and wake times, adequate hydration, moderated caffeine intake, gentle aerobic exercise, stress reduction strategies, cognitive behavioural therapy, and biofeedback all have value and carry no fetal exposure risk. These measures are not secondary add-ons. In many patients they form the backbone of management and improve resilience once medication options narrow during pregnancy.

Key Counselling Points

A strong preconception consultation should include clear, practical counselling. Women should be reassured that migraine often improves substantially, sometimes dramatically, by the second trimester. They should also understand that enhanced obstetric awareness may be appropriate because migraine is associated with preeclampsia, stroke, and preterm birth. The safety profile of all current acute and preventive medications should be reviewed by trimester, and a written plan for acute attacks is often useful, especially if severe migraine has previously led to urgent care or emergency department attendance. Women should also be informed that non-invasive neuromodulation devices may offer a drug-free option during pregnancy when appropriate.

Acute Treatment of Migraine During Pregnancy

Acute treatment of migraine during pregnancy should follow a stepwise and trimester-aware approach. The aim is to achieve meaningful relief using the safest available treatment at the lowest effective dose and for the shortest necessary duration. The presence of nausea and vomiting is clinically important because it can impair oral absorption and reduce the usefulness of otherwise appropriate oral medications.

First-Line Acute Therapy: Paracetamol (Acetaminophen)

Paracetamol remains the first-line acute treatment throughout all trimesters of pregnancy. The usual recommended dose is 1,000 mg up to three times daily. It may be combined with caffeine, provided total caffeine intake is kept to 200 mg per day or less. Paracetamol has an extensive track record of use in pregnancy and remains the safest default starting point for acute migraine treatment.

When migraine is accompanied by nausea or vomiting, metoclopramide is a useful adjunct. It is considered safe throughout pregnancy and may improve headache as well as nausea. Diphenhydramine is often added to reduce the risk of akathisia or other extrapyramidal side effects associated with metoclopramide. This combination is well established and can be particularly useful when oral intake is limited.

Second-Line Acute Therapy: Triptans

If paracetamol-based treatment is insufficient, sumatriptan is the preferred second-line agent. Among all triptans, sumatriptan has by far the greatest amount of pregnancy safety data. Large safety reviews have not shown a consistent association with major congenital malformations or other major adverse fetal outcomes. Some reviews have reported a modest increased risk of hyperactivity and emotionality at three years of age, but overall the evidence remains far more reassuring for sumatriptan than for other drugs in the class.

Other triptans such as rizatriptan, eletriptan, and zolmitriptan have less robust pregnancy data. That does not automatically mean they are unsafe, but it does mean they do not carry the same level of reassurance. If a woman was particularly well controlled on a non-sumatriptan triptan before pregnancy, an individualised risk-benefit discussion may still be appropriate. In patients with marked nausea, intranasal or subcutaneous sumatriptan may be preferable to tablets because absorption is more reliable.

Sumatriptan is also generally compatible with breastfeeding. Only small amounts enter breast milk. Some guidance suggests expressing and discarding milk for 12–24 hours after use, though this is not universally required.

NSAIDs — Trimester-Specific Guidance

NSAIDs require careful trimester-specific handling. They are not uniformly safe throughout pregnancy, and timing is central to risk assessment. In the first trimester, NSAIDs are generally avoided because of associations with miscarriage and possible congenital malformations, particularly with repeated or prolonged exposure. In the second trimester, short-term use may be acceptable and can be considered cautiously. In emergency settings, IV ketorolac may be used during the second trimester. In the third trimester, NSAIDs should be avoided because they can cause premature constriction of the ductus arteriosus, oligohydramnios, impaired fetal renal function, and neonatal pulmonary hypertension.

Medications to Avoid

Some drugs should not be used for migraine during pregnancy. Ergot alkaloids, including ergotamine and dihydroergotamine, are contraindicated because they can stimulate uterine contractions and cause uterine vasoconstriction. Butalbital-containing compounds should be avoided because they do not improve outcomes compared with safer alternatives and carry risk of medication overuse headache as well as fetal cardiac concerns. Opioids should generally be avoided because of medication overuse headache, dependence, neonatal withdrawal, and concern about fetal neurodevelopment with prolonged exposure. Gepants and lasmiditan currently lack sufficient pregnancy safety data and should also be avoided. If corticosteroids are needed for a severe refractory attack, oral prednisone or methylprednisolone are preferred over IV or IM dexamethasone because dexamethasone crosses the placenta more readily.

Emergency and Status Migrainosus Management

Intractable migraine or status migrainosus during pregnancy requires a structured escalation pathway. ACOG recommends a stepwise protocol that begins with safer systemic therapies and escalates only when necessary.

This sequence reinforces an important principle: intervention is not presented as a first-line shortcut, but as a reserved escalation step for selected patients who have not responded adequately to safer and more established measures.

Comprehensive Medication Safety Reference

A clear medication safety reference is particularly valuable in pregnancy because both patients and clinicians often need quick reassurance about what is acceptable, what is trimester-dependent, and what should be avoided.

Acute Medications by Trimester

This table makes the hierarchy clear. Paracetamol sits at the safest end. Sumatriptan is the triptan of choice. NSAIDs are governed by gestation. Several newer or less well-studied agents remain inappropriate because the evidence base in pregnancy is simply too limited.

Preventive Medications — Safety in Pregnancy

This is one of the most clinically useful parts of the review because it allows rapid distinction between established compatible options, risk-benefit options, and clearly contraindicated agents. The difficult grey area is onabotulinumtoxinA: ACOG takes a cautious stance, but some post-marketing data is reassuring and systemic exposure is minimal. That does not make it routine, but it explains why carefully individualised decisions may sometimes arise in severe chronic refractory migraine.

Non-Pharmacological and Behavioural Treatments

Non-pharmacological treatment is central to migraine management during pregnancy. These approaches avoid fetal exposure entirely and can reduce both migraine frequency and reliance on medication. They are particularly important because pregnancy narrows the safe pharmacological options and because lifestyle-related triggers often become more prominent during gestation.

Lifestyle and Behavioural Strategies

Regular sleep timing is important because both sleep deprivation and sleep excess can trigger migraine. A consistent sleep and wake schedule, including weekends, can therefore reduce attack frequency. Trigger management using a headache diary is often helpful, particularly when patterns relate to dehydration, missed meals, stress, disrupted sleep, or caffeine fluctuation. Caffeine may still be used, but it should generally be kept below 200 mg per day. Hydration deserves specific emphasis because dehydration is both a direct migraine trigger and a common issue in pregnancy.

Moderate aerobic exercise can also play a meaningful role. In uncomplicated pregnancy, regular moderate-intensity exercise is safe and may reduce migraine frequency and severity while also benefiting stress regulation and mood. Stress management techniques such as progressive muscle relaxation, mindfulness, and breathing exercises can further reduce attack burden.

Cognitive behavioural therapy has good evidence for reducing migraine-related disability and can be particularly valuable when anxiety or depressive symptoms coexist. Biofeedback, especially thermal and electromyographic approaches, can produce substantial frequency reduction and is entirely safe in pregnancy. Acupuncture also has supportive evidence for migraine prevention and is generally considered safe when performed appropriately, avoiding points specifically contraindicated in pregnancy.

Non-Invasive Neuromodulation Devices

Non-invasive neuromodulation deserves special attention because it offers a drug-free option for both acute treatment and prevention. These devices are particularly attractive during pregnancy because they have no systemic absorption and no placental drug transfer. The evidence base in pregnancy itself remains limited, largely because pregnant women are commonly excluded from clinical trials, but the general safety profile of these devices makes them a meaningful option in appropriately selected patients.

In practice, access and cost remain barriers to neuromodulation. Insurance or funding coverage is inconsistent, and this may limit uptake despite the conceptual attractiveness of these devices in pregnancy. Still, they deserve inclusion in a comprehensive pregnancy migraine review because they offer a genuine non-pharmacological alternative when medication choices are restricted.

Peripheral Nerve Blocks in Pregnancy

Peripheral nerve blocks, particularly greater occipital nerve blocks, have an evidence-supported role in pregnancy, but they must be positioned carefully. They are not routine first-line treatment for typical pregnancy migraine. Rather, they become relevant in selected clinical scenarios such as status migrainosus, refractory attacks that have not responded to standard medication, or short-term transitional prevention when repeated systemic medication exposure is undesirable or poorly tolerated. This evidence-based positioning is important and should be preserved.

The reason nerve blocks are of interest in pregnancy is their safety profile. They provide localised treatment with minimal systemic absorption, thereby avoiding meaningful fetal drug exposure. This is not an argument to overuse them, but it is the reason they remain valuable when escalation is genuinely needed. The 2025 American Headache Society guideline assigns greater occipital nerve blocks a Level A recommendation for acute migraine treatment in the emergency department, and pregnancy cohort data has not shown increased miscarriage, fetal harm, or significant pregnancy complications.

Indications During Pregnancy

Two broad pregnancy scenarios support the use of peripheral nerve blocks. The first is status migrainosus or severe refractory migraine that has not responded to oral medication and often also not responded adequately to IV treatment. The second is short-term prophylaxis in women with frequent disabling migraine where ongoing repeated systemic medication exposure is undesirable.

In case series and cohort data, meaningful reductions in pain were seen both immediately after the procedure and at 24 hours. Serial greater occipital nerve blocks also reduced the number of days per month on which acute medications were required. This matters clinically because one of the goals in pregnancy is not merely pain reduction, but also reduction in repeated systemic drug exposure.

Greater Occipital Nerve (GON) Block

The greater occipital nerve arises from the C2 dorsal ramus and becomes superficial near the superior nuchal line, medial to the occipital artery. It can therefore be targeted relatively simply using landmark-based technique. The usual target is approximately 1.5–2 cm medial to the occipital artery pulsation and around 2 cm lateral and inferior to the external occipital protuberance.

This is a relatively straightforward procedure, but good technique still matters, both for efficacy and for minimising discomfort or vascular injection risk.

Local Anaesthetic Selection for Pregnancy

The choice of injectate is especially important in pregnancy. Lidocaine and bupivacaine are the preferred agents because both have extensive safety data from decades of obstetric anaesthesia. At the doses used in peripheral nerve blocks, systemic exposure is minimal and there is no convincing evidence of increased risk of birth defects or miscarriage.

Maximum safe doses remain well above the amounts used in occipital nerve blocks, providing a wide safety margin in routine practice.

Corticosteroids — Important Caveat

One of the most important pregnancy-specific points in the interventional section is the role of steroids. The evidence does not demonstrate clear additional benefit from adding corticosteroids to local anaesthetic for migraine nerve blocks. Since local anaesthetic alone is usually sufficient and has a far more reassuring safety profile in pregnancy, local anaesthetic-only blocks are preferred.

This matters because pregnancy changes the threshold for adding non-essential drugs. Steroids are not automatically dangerous in every circumstance, but they do increase fetal exposure concerns, especially in early pregnancy, and if there is no consistent evidence that they improve outcomes in migraine blocks, routine use becomes difficult to justify. If steroid use were considered in a particularly refractory case, methylprednisolone or triamcinolone would generally be more acceptable than dexamethasone, because dexamethasone crosses the placenta more readily. The core practical message remains unchanged: local anaesthetic-only blocks are the preferred standard in pregnancy.

Additional Nerve Block Targets

Although the greater occipital nerve is the best established target, other branches may be selected according to pain distribution. Supraorbital and supratrochlear blocks may help frontal pain, lesser occipital blocks may extend coverage laterally, and auriculotemporal blocks may be useful in temporal-predominant migraine. These should still be regarded as targeted tools for selected pain patterns rather than routine additions for every patient.

Safety Profile of Nerve Blocks in Pregnancy

Peripheral nerve blocks are generally well tolerated in pregnancy. Most adverse effects are mild and transient, such as temporary local discomfort, minor bleeding, numbness in the blocked distribution, or occasional lightheadedness. Serious complications are rare, and pregnancy cohort studies have not reported increased miscarriage or negative fetal outcomes. Again, this supports their role as a reasonable escalation option when clinically indicated, not as an overused early intervention.

Sphenopalatine Ganglion (SPG) Block in Pregnancy

The sphenopalatine ganglion is a parasympathetic ganglion located in the pterygopalatine fossa and connected to trigeminal-autonomic pathways involved in migraine. Blocking the SPG can reduce pain, especially in migraine associated with autonomic symptoms such as lacrimation, nasal congestion, or prominent facial discomfort. As with peripheral nerve blocks, the relevance of SPG block in pregnancy lies in its potential role as a selected escalation strategy rather than a routine frontline treatment.

The American Academy of Pain Medicine has identified SPG block as an option with minimal side effects in special populations, including pregnancy, where preventive pharmacological options are more restricted. The reason it enters the discussion is again the limited systemic absorption of local anaesthetic and the resulting lack of meaningful fetal exposure.

Evidence in Status Migrainosus

Retrospective data in patients with refractory migraine who had failed multiple abortive medications suggests that SPG block can produce rapid pain reduction. This makes it relevant in selected cases of status migrainosus or refractory migraine with autonomic features, although the evidence base is not as strong as for greater occipital nerve blocks. Its role is therefore supportive and situational, not central.

Techniques

The preferred approach in pregnancy, when used, is usually the least invasive one. A transnasal protocol typically involves placing the patient supine with slight head extension, advancing the catheter gently along the nasal floor toward the pterygopalatine region, delivering a small volume of lidocaine or bupivacaine to each side, and keeping the patient supine for a short period afterwards. Relief may occur within 15–30 minutes, and transient throat numbness, unpleasant taste, or lacrimation can occur.

Practical Treatment Algorithm

A practical algorithm helps bring the evidence together and keeps treatment hierarchy clear. Non-pharmacological measures and the safest systemic treatments come first. Interventional procedures are positioned as escalation options in selected refractory scenarios rather than default steps.

This algorithm is especially important because it prevents both undertreatment and overtreatment. Evidence-based care in pregnancy is not passive, but it is also not unnecessarily aggressive.

Management During Breastfeeding

Migraine treatment during breastfeeding is generally less restrictive than during pregnancy, though infant exposure through breast milk still matters. Many of the medications used acutely for migraine are compatible with lactation when used appropriately.

The relative relaxation in prescribing during breastfeeding is helpful, but it should not be confused with lack of caution. Drug choice still deserves thought, especially in premature infants or when repeated doses are needed.

Key Clinical Pearls

Several clinical messages emerge consistently from the evidence. Migraine often improves in the second trimester, and this is an important source of reassurance during counselling. Severe migraine should not be left untreated, because untreated attacks have real consequences for both maternal wellbeing and pregnancy health. Women with migraine, especially migraine with aura, should be monitored more carefully for vascular and obstetric complications. Sumatriptan is the triptan of choice during pregnancy because its safety evidence is stronger than that of other triptans. NSAIDs are not uniformly unsafe, but they are trimester dependent and must be used accordingly. Peripheral nerve blocks are among the most evidence-based interventional options when escalation is needed, and local anaesthetic-only techniques are preferred over steroid-containing blocks in pregnancy. Non-invasive neuromodulation devices deserve consideration as drug-free options. CGRP monoclonal antibodies must be stopped well before conception, and valproate and topiramate remain clearly contraindicated. Shared decision-making is essential throughout because the evidence base, while improving, still contains important grey areas.

Quick Reference — Evidence and Safety Summary

This summary captures the central message of the whole review: treatment during pregnancy is not about doing nothing, but about choosing the safest effective intervention in the correct order.

At-a-Glance Treatment Algorithm

For readers who want a rapid practical overview, the following stepwise summary brings the article together in a single treatment pathway. This is not a replacement for the fuller discussion above, but a final quick-reference guide.

Pregnancy Drug Safety — Traffic Light Summary

A simple traffic-light summary can be useful for quick reference, provided it is interpreted carefully. Some medications are genuinely acceptable, some require trimester-specific caution or individualised judgement, and some should be avoided altogether.

This kind of summary is deliberately simplified, so it should always be read alongside the fuller tables above. NSAIDs, in particular, belong in the amber category because they are not uniformly unsafe; their use depends heavily on trimester.

Final Summary

Migraine management during pregnancy requires balance rather than therapeutic nihilism. For many women, symptoms improve naturally as pregnancy progresses, but a significant minority continue to experience disabling attacks and need active treatment. Evidence-based care begins with education, trigger control, hydration, sleep regulation, and behavioural strategies. It then progresses through the safest acute pharmacological treatments, with paracetamol and sumatriptan occupying important positions. Preventive treatment, when needed, relies on the safest established options such as propranolol or verapamil, while clearly contraindicated agents must be stopped before conception.

Interventional treatments also have a place, but that place must remain properly defined. Peripheral nerve blocks and SPG blocks are not routine first-line therapies for pregnancy migraine. Their value lies in selected refractory cases, status migrainosus, or situations in which systemic medication exposure needs to be minimised. When they are used, pregnancy safety considerations matter greatly, which is why local anaesthetic-only techniques are preferred and steroid use should be approached cautiously. This balanced positioning is entirely consistent with an evidence-based, guideline-aware Pain Spa article.

Ultimately, the most important message is simple: migraine during pregnancy should be treated safely, thoughtfully, and early enough to prevent unnecessary suffering. The correct goal is neither undertreatment nor overtreatment, but well-judged, individualised care.

13. References

1. American College of Obstetricians and Gynecologists (ACOG). Headaches in Pregnancy and Postpartum. ACOG Clinical Practice Guideline, 2022.

2. American Headache Society (AHS). The American Headache Society Consensus Statement: Treatment of Migraine During Pregnancy and Lactation. Headache. 2021;61(7):1021–1039.

3. International Headache Society (IHS). Global Practice Recommendations for Migraine Management. Cephalalgia. 2024.

4. MacGregor EA. Migraine in Pregnancy and Lactation: A Clinical Review. Lancet Neurology. 2020;19(3):239–248.

5. Robbins MS et al. Treatment of Cluster Headache and Migraine in Pregnancy. Current Pain and Headache Reports. 2019;23:27.

6. Agency for Healthcare Research and Quality (AHRQ). Management of Primary Headaches in Pregnancy. Systematic Review, 2021.

7. Nezvalová-Henriksen K et al. Exposure to Triptans During Pregnancy and the Risk of Adverse Pregnancy Outcomes. Cephalalgia. 2010;30(3):292–299.

8. Marchenko A et al. Safety of Sumatriptan Use During Pregnancy: A Systematic Review. Headache. 2015.

9. Källén B, Nilsson E. Maternal Use of Analgesics and Pregnancy Outcomes. European Journal of Clinical Pharmacology. 2011.

10. Bateman BT et al. Nonsteroidal Anti-inflammatory Drug Use During Pregnancy and Risk of Adverse Outcomes. Obstetrics & Gynecology. 2013.

11. Olesen J et al. The International Classification of Headache Disorders (ICHD-3). Cephalalgia. 2018.

12. Silberstein SD. Preventive Migraine Treatment in Special Populations. Neurology. 2020.

13. Ornello R et al. Migraine and Pregnancy: Epidemiology and Risk Management. Neurological Sciences. 2020.

14. European Medicines Agency (EMA). Valproate and Topiramate Safety Restrictions in Pregnancy. EMA Safety Communication.

15. American Headache Society. 2025 Guideline Update: Interventional Treatments for Migraine. AHS Clinical Guideline, 2025.

16. Blumenfeld A et al. Greater Occipital Nerve Block for Migraine: Evidence-Based Review. Headache. 2013.

17. Robbins MS, Robertson CE. Peripheral Nerve Blocks for Headache Disorders. Current Pain and Headache Reports. 2018.

18. Gelfand AA et al. Greater Occipital Nerve Blocks in Pregnant Patients with Migraine. Headache. 2021.

19. Ashkenazi A et al. Greater Occipital Nerve Block for Migraine and Other Headaches. Current Neurology and Neuroscience Reports. 2010.

20. American Academy of Pain Medicine (AAPM). Interventional Treatments for Headache Disorders. Clinical Guidance Statement.

21. Cady RK et al. Sphenopalatine Ganglion Block for the Treatment of Migraine. Headache. 2015.

22. Tassorelli C et al. Non-invasive Neuromodulation for Migraine: IHS Evidence-Based Review. Cephalalgia. 2022.

23. Puledda F et al. Neuromodulation in Migraine: Current Evidence and Future Directions. Lancet Neurology. 2021.

24. Buse DC et al. Behavioral Treatments for Migraine. Neurology. 2019.

25. Linde K et al. Acupuncture for Migraine Prevention. Cochrane Database of Systematic Reviews. 2016.

26. National Library of Medicine. Drugs and Lactation Database (LactMed). Updated 2024.

This article has been prepared for Pain Spa as a comprehensive clinical reference for the management of migraine in pregnancy. All management decisions should be individualised in the context of current guidelines, gestational age, comorbidities, and patient preferences. This is a rapidly evolving field — guidelines should be consulted for the most current recommendations.

Evidence-based clinical reference | Pain Spa 2026